https://www.indianpharmapost.com/poly-medicure-posts-q2-fy26-consolidated-net-profit-at-rs-9183-cr-181842025-11-09T00:00:00+05:30always0.9https://www.indianpharmapost.com/syngene-international-reports-q2-fy26-consolidated-pat-at-rs-671-cr-181852025-11-09T00:00:00+05:30always0.9https://www.indianpharmapost.com/piramal-pharma-posts-q2-fy26-consolidated-loss-at-rs-9922-cr-181862025-11-09T00:00:00+05:30always0.9https://www.indianpharmapost.com/solara-active-pharma-sciences-posts-q2-fy26-consolidated-loss-at-rs-1010-cr-181872025-11-09T00:00:00+05:30always0.9https://www.indianpharmapost.com/caplin-point-laboratories-reports-q2-fy26-consolidated-pat-at-rs-15445-cr-181882025-11-09T00:00:00+05:30always0.9https://www.indianpharmapost.com/sms-pharmaceuticals-post-q2-fy26-consolidated-pat-at-rs-2531-cr-181892025-11-09T00:00:00+05:30always0.9